Carregant...

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzumab in MBC in patients who had progressed on or within 12 months of receiving a trastuzumab-c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mani, Aruna, Roda, Julie, Young, Donn, Caligiuri, Michael A., Fleming, Gini F., Kaufman, Peter, Brufsky, Adam, Ottman, Susan, Carson, William E., Shapiro, Charles L.
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2997435/
https://ncbi.nlm.nih.gov/pubmed/19051009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-008-0251-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!